Clinical Briefing:
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
For Diagnosis of Thoracic Adenopathy & Lung Cancer Staging
November/December 2008
Interventional pulmonologists at the Hospital of the University
of Pennsylvania are using a new minimally invasive technology,
endobronchial ultrasound-guided transbronchial needle aspiration
(EBUS-TBNA), to diagnose thoracic adenopathy and to stage lung
cancer less invasively. EBUS-TBNA integrates ultrasonography,
video-enhanced visualization and real-time echogenic needle
aspiration into a single, flexible, bronchoscopy unit (Figure 1).
Using EBUS-TBNA,
Penn interventional pulmonologists can observe and differentiate
all mediastinal and hilar structures with the integrated
ultrasound videobronchoscope. The unit’s dedicated 22-gauge
needle can be seen with standard video visualization. More
importantly, the needle is visualized under real-time ultrasound
during the lymph node biopsy. This dedicated aspiration needle
can be extended to roughly 4 cm and is capable of obtaining
large core biopsies for cytologic and histopathologic analysis.
With
this technology, Penn interventional pulmonologists can diagnose
thoracic adenopathy and stage lung cancer with a minimally
invasive approach using only conscious sedation in a same-day
outpatient procedure. Clinical studies have shown that for
lung cancer diagnosis and staging, the sensitivity and accuracy
of EBUS-TBNA are nearly equivalent to the current gold standard,
cervical mediastinoscopy. At Penn, this technology is actively
being used to diagnose thoracic adenopathy and to stage cancers
earlier and less invasively than previously possible.

The EBUS-TBNA unit is a flexible bronchoscope containing an electronic convex array ultrasound transducer, a miniature video camera and a dedicated 22-gauge echogenic aspiration needle that is seen real-time during biopsy.
|
|
Case Study
Mr. R., a 67-year-old man with an 80 pack-year history of
tobacco abuse presented to his primary physician with cough.
When his cough did not respond to antibiotics, his primary
physician ordered a chest X-ray which demonstrated a right
lung mass. The patient was referred to Penn Interventional
Pulmonary Services for evaluation and diagnosis. A chest
CT scan demonstrated a 4.2 x 3.4 cm right upper lobe lung mass with a
1.4 cm right hilar, a 1.1 cm right paratracheal, and 1.4 cm subcarinal
lymph node (Figure 2). The Interventional Pulmonology Program then
performed an EBUS-TBNA of the subcarinal and right paratracheal lymph
nodes (Figure 3).

Chest CT scan showing a right upper lobe lung mass and an enlarged right paratracheal lymph node (1.1 cm).

EBUS-TBNA image demonstrating the hyperechoic needle (arrow) within the lymph node. The lymph node can be differentiated easily from the surrounding pulmonary artery (PA) and aorta (AO) to allow for safe and effective sampling.
|
|
On-site cytologic analysis demonstrated lymphocytes without
lung cancer in the subcarinal lymph node, but did demonstrate
lung cancer in his right paratracheal lymph node. With
the diagnosis of advanced regional lung cancer, the patient
was not deemed a surgical candidate and was begun on concurrent
definitive chemoradiotherapy. The patient has had a very
good response to aggressive therapy.
Our Team of Faculty
Interventional Pulmonology Services at the Hospital of the
University of Pennsylvania offers a broad array of diagnostic,
therapeutic and palliative airway and pleural procedures.
Treatments offered include flexible and rigid bronchoscopy
with laser, electrocautery, and argon plasma tumor debulking
modalities, endobronchial stenting, balloon brocho-plasty, early lung cancer
detection via LIFE-Lung fluorescence bronchoscopy, endobronchial
brachytherapy, photodynamic therapy, and indwelling tunneled catheters and
pleuroscopy for pleural effusions.
The program is actively involved in many
clinical trials evaluating various novel immunotherapeutic
treatments for patients with lung cancer, mesothelioma, and
metastatic pleural disease. In addition, the program participates
in several clinical trials investigating novel bronchoscopic
treatments for emphysema and asthma.
Daniel Sterman, MD
Associate Professor of Medicine
Director,
Interventional Pulmonology and Thoracic Oncology
Andrew
Haas, MD, PhD
Assistant Professor of Medicine
Medical Director,
Interventional Pulmonology and Thoracic Oncology
Colin Gillespie,
MD
Instructor of Medicine
Director of Education,
Interventional Pulmonology and Thoracic Oncology
Anil Vachani,
MD
Assistant Professor of Medicine
Director of Clinical Research,
Interventional Pulmonology and Thoracic Oncology
Locations
Patient appointments are available at:
Penn Lung Center
Hospital of the University of Pennsylvania
Interventional Pulmonology Services
3 Ravdin, Suite F
3400 Spruce Street
Philadelphia, PA 19104
To refer a patient and/or consult
with a doctor, call 800-789-PENN (7366)
or refer
a patient online.
|

|
Referring Physicians: To speak with a Penn physician
or refer a patient, contact PennHealth through the secure online
referral form or by calling
1-800-789-PENN
(7366). |
 |
 |
 |
|